Evidence map›Paper›PMID 34157804›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2021

[Comprehensive Treatment of An Advanced Lung Cancer Patient with 
EGFR Driver Gene Positive].

Shuai Wang, Xianjun Min, Yingshun Yang, Guotian Pei, Qiang Liu, Jun Liu, Yuqing Huang

Open access · greenAbstract readCase Reports
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shuai WangDepartment of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.
Xianjun MinDepartment of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.
Yingshun YangDepartment of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.
Guotian PeiDepartment of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.
Qiang LiuDepartment of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.
Jun LiuDepartment of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.
Yuqing HuangDepartment of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.
Beijing Haidian Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most common malignant tumor and the leading cause of cancer-related death worldwide. Most of the patients have distant metastasis when visiting the doctor, which seriously affects the survival time and quality of life of the patients. With the development of molecular targeted drugs, lung cancer treatment has been transformed from traditional chemotherapy to targeted therapy and precision medicine has been gradually applied in clinical practice, which can make lung cancer patients live longer and have a better quality of life. We present a case of advanced lung cancer patient who presented to Department of Thoracic Surgery of Beijing Haidian Hospital five years ago. We chose the reasonable treatment options though the genetic tests and circulating tumor DNA tests. We summarized the adverse reactions in the whole course of treatment. The comprehensive therapy we utilized, including targeted therapy, chemotherapy, antiangiogenic agents and local radiotherapy, have resulted in our patient with remaining alive. For advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation positive, individualized treatment was conducted based on precise genotyping and dynamic monitoring, which can not only control the tumor, but also have mild toxic and side effects. The survival time of the patients was prolonged and the quality of life was guaranteed.
.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsCirculating Tumor DNACombined Modality TherapyErbB ReceptorsHumansProtein Kinase InhibitorsQuality of LifeTreatment OutcomeAntineoplastic AgentsCirculating Tumor DNAEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsAdverse reactionEepidermal growth factor receptor-tyrosine kinase inhibitorLung neoplasms

Identifiers

PMID34157804
PMCPMC8246388
OpenAlexW3173319723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.